The FDA is get­ting its hands on a ‘hu­man em­u­la­tion sys­tem,’ and Em­u­late hopes they nev­er let go


The fu­ture for the or­gans-on-chips in­dus­try will de­pend to a large ex­tent on the FDA’s abil­i­ty to un­der­stand how it works as well as its prac­ti­cal, near-term po­ten­tial for re­plac­ing an­i­mals in pre­clin­i­cal re­search as the sys­tem evolves. And now reg­u­la­tors are about to get some hands-on ex­pe­ri­ence with a col­lab­o­ra­tive ef­fort to build a hu­man em­u­la­tion sys­tem in­side the agency.

The FDA has agreed to work with Em­u­late, a spin­off of the Wyss In­sti­tute which has been de­vel­op­ing and im­prov­ing on the in­dus­try stan­dard in the field, snag­ging part­ner­ships with the likes of Mer­ck and J&J. The work will be done un­der a Co­op­er­a­tive Re­search and De­vel­op­ment Agree­ment (CRA­DA), cre­at­ing a plat­form for tox test­ing for prod­ucts like foods, di­etary test­ing and cos­met­ics.

“The fo­cus is to as­sess the sys­tem’s ca­pa­bil­i­ty,” says Geral­dine Hamil­ton, pres­i­dent and CSO, “putting the chips, soft­ware and in­stru­men­ta­tion in the hands of FDA re­searchers, so they can bet­ter un­der­stand its po­ten­tial in sur­pass­ing an­i­mals for this kind of work.”


The agree­ment calls for a full-time com­mit­ment of five staffers at the FDA for three years, with a sim­i­lar com­mit­ment com­ing from Em­u­late.

This part­ner­ship isn’t about re­plac­ing an­i­mals for tox­i­col­o­gy stud­ies in pre­clin­i­cal drug re­search, but when I sug­gest­ed that would be the ul­ti­mate goal for where the col­lab­o­ra­tion could be head­ed, giv­ing the FDA more con­fi­dence in its ap­pli­ca­tions, she quick­ly con­curred.

“That is ex­act­ly the pur­pose,” says Hamil­ton.

The tech al­so isn’t ex­act­ly brand new to the FDA.

“Suzanne Fitz­patrick, se­nior ad­vi­sor for tox­i­col­o­gy at the FDA,” adds the CSO, “has been in­volved in col­lab­o­ra­tive re­search ef­forts since the time the tech­nol­o­gy was un­der de­vel­op­ment at the Wyss In­sti­tute at Har­vard.” But it is a big step for­ward.

“This is the start­ing point,” says Hamil­ton. “We are al­ready do­ing sim­i­lar ef­forts with in­dus­try part­ners, in the food in­dus­try, on very sim­i­lar col­lab­o­ra­tions.”

Fitz­patrick had this to say in a blog post to­day:

In some ways, sci­ence is like a recipe in that both can go through a num­ber of in­car­na­tions be­fore they work. There’s a lot of ex­per­i­ment­ing and tweak­ing, col­lab­o­rat­ing and com­par­ing. And that’s what we’ll be do­ing at FDA with the or­gans-on-chips re­search. Sci­ence is the foun­da­tion of FDA’s de­ci­sions but many peo­ple don’t re­al­ize how much sci­en­tif­ic re­search is con­duct­ed by the agency. We’re ex­cit­ed to be at the fore­front of this ground-break­ing re­search, which may one day be rou­tine­ly used to safe­guard pub­lic health.

Birthing a new tech­nol­o­gy is no quick or easy prospect. But Em­u­late is mak­ing mea­sur­able progress and plans on more high-pro­file part­ner­ships lat­er in the year.

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive piv­otal for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma.

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

We don’t know what the data are yet, but DREAMM-2 falls on the heels of a promising set of data delivered 5 months ago for DREAMM-1. There investigators noted that complete responses among treatment-resistant patients rose to 15% in the extra year’s worth of data to look over, with a median progression-free survival rate of 12 months, up from 7.9 months reported earlier. The median duration of response was 14.3 months.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Bob Smith, Pfizer

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

Three years ago, Pfizer anted up $150 million in cash to buy Bamboo Therapeutics in Chapel Hill, NC as it cautiously stuck a toe in the small gene therapy pool of research and development.

Company execs followed up a year later with a $100 million expansion of the manufacturing operations they picked up in that deal for the UNC spinout, which came with $495 million in milestones.

And now they’re really going for it.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Video: Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha and Shoibal Dat­ta

During BIO this year, I had a chance to moderate a panel among some of the top tech experts in biopharma on their real-world use of artificial intelligence in R&D. There’s been a lot said about the potential of AI, but I wanted to explore more about what some of the larger players are actually doing with this technology today, and how they see it advancing in the future. It was a fascinating exchange, which you can see here. The transcript has been edited for brevity and clarity. — John Carroll

As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

AstraZeneca bet big on the future of their PD-L1 Imfinzi combined with the experimental CTLA-4 drug tremelimumab. But once again it’s gone down to defeat in a major Phase III study — while adding damage to the theory involving targeting cancer with a high tumor mutational burden.

Early Wednesday the pharma giant announced that their NEPTUNE study had failed, with the combination unable to beat standard chemo at overall survival in high TMB cases of advanced non-small cell lung cancer. We won’t get hard data until later in the year, but the drumbeat of failures will call into question what — if any — future this combination can have left.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Why would Am­gen want to buy Alex­ion? An­a­lysts call hot­ly ru­mored takeover un­like­ly, but seize the mo­ment

A rumor that Amgen is closing in on buyout deal for Alexion has sparked a guessing game on just what kind of M&A strategy Amgen is pursuing and how much Alexion is worth.

Mizuho analyst Salim Syed first lent credence to the report out of the Spanish news outlet Intereconomía, which said Amgen is bidding as much as $200 per share. While the source may be questionable, “the concept of this happening doesn’t sound too crazy to me,” he wrote.